About Curetis
Curetis is a Healthcare company based in Holzgerlingen (Germany) founded in 2007, and was acquired by OpGen in September 2019. Molecular diagnostics platform is provided for infectious disease detection. Curetis has raised $127.14 million across 14 funding rounds from investors including Qiagen, OpGen and European Investment Bank. The company has 55 employees. Its chief executive, as recorded, is Raju Jha. Curetis offers products and services including Unyvero and Unyvero A50 Solution. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Curetis GmbH.
Company details
The company was founded in 2007 in Holzgerlingen, Germany, and operates in the molecular diagnostics sector. A platform for detecting infectious diseases through multiparameter PCR testing is developed, targeting bacterial infections in hospitalized patients. The Unyvero A50 System is utilized with various cartridges to identify pathogens and resistance genes for conditions like pneumonia and implant infections, with results obtained in 4-5 hours.
- Headquarters Holzgerlingen, Germany
- Employees 55
- Stage Acquired
- SectorsHealthcare
- Website curetis.com
- Social LinkedIn X
- Acquired by OpGen (Sep 2019)
- Legal Name Curetis Gmbh.
Products & Services of Curetis
Curetis offers a comprehensive portfolio of products and services, including Unyvero and Unyvero A50 Solution.
Rapid molecular tool for detecting pathogens in infections.
Provides fast results for clinical syndromes with minimal training.
Funding Insights of Curetis
Curetis has successfully raised a total of $127.14M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $409.68 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.14M
- Total Rounds 14
- Last Round Grant — $409,682
- First Round $1.95M
(Jun 2008)
- Investors Count 12
Latest 10 of 14 funding rounds of Curetis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $409,682 | Grant | – | – | |
| Jul 2020 | $5.65M | Debt – Conventional | – | – | |
| May 2019 | $5.58M | Debt – Conventional | – | – | |
| May 2019 | $1.67M | Series C | – | Yorkville Advisors | – |
| Oct 2018 | $23.18M | Series C | – | Yorkville Advisors | – |
| Apr 2018 | $15.06M | Series B | – | – | – |
| Dec 2016 | $10.56M | Debt – Conventional | – | – | |
| Nov 2014 | $17.96M | Series B | – | HBM Partners | |
| Apr 2013 | $16.31M | Series B | – | HBM Partners | |
| Oct 2011 | $13.36M | Series A | – | Forbion |
13 investors in total: 13 institutional.
Investors in Curetis
Curetis has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiagen, OpGen and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Investments are made by CD-Venture in early-stage life sciences startups. | cd-venture.com | Heidelberg, Germany | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany | |
Offers flexible capital to micro-cap and small-cap firms for growth. | 2001 | yorkvilleadvisors.com | Mountainside, United States | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for Curetis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Curetis
27 people are tracked at Curetis (10 in leadership, 9 in board & advisors, 8 in team); the tracked headcount is 55.
| Name | Role | Group |
|---|---|---|
Raju Jha | CEO | Leadership |
Oliver Schacht | Managing Director | Leadership |
Johannes Bacher | COO | Leadership |
Ines Jelinek | Head of Accounting and Controlling | Leadership |
Sandra Barth | Head of Clinical Trial Operations | Leadership |
Anke Möckel | Head Of Business Services | Leadership |
Albert Weber | CFO | Leadership |
Faranak Atrzadeh | Chief Marketing & Scientific Affairs Officer | Leadership |
Karin Konrad | Head Of Human Resource Management | Leadership |
Karsten Müller | Head Of Quality Regulatory Affairs | Leadership |
William E. Rhodes III | Chairman | Board & advisors |
Don Elsey | Director | Board & advisors |
Prabhavathi Fernandes | Director | Board & advisors |
Yvonne Schlaeppi | Director | Board & advisors |
Debra A. Goff | Advisor | Board & advisors |
Stefan Riedel | Advisor | Board & advisors |
Patricia Simner | Advisor | Board & advisors |
James W. Snyder | Advisor | Board & advisors |
Mario Crovetto | Director | Board & advisors |
Christian Flohr | QA Expert | Team |
7 more people are available in the full profile.
Complete people profiles for Curetis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Curetis
4 dated milestones of Curetis across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Curetis is founded.
- Funding First funding round of $1.9M.
- Exit Acquired by OpGen.
- Funding Latest funding round, Grant, of $410K.
Web traffic of Curetis
Websites that share an audience with Curetis (curetis.com).
Websites whose visitors overlap most with Curetis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
triconference.com | triconference.com | 100% | #1,678,419 | – | |
| elitechgroup.com | 63% | 18.4K | #1,346,579 | View details | |
blue.regence.com | blue.regence.com | 62% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curetis
Complete news archive for Curetis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curetis
Curetis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Curetis is headquartered in Holzgerlingen, Germany. It is registered at Holzgerlingen, Baden-wurttemberg, Germany.
Raju Jha is the CEO of Curetis, as recorded in our data.
Curetis is a funded company, having raised a total of $127.14M across 14 funding rounds to date. The company's 1st funding round was a Series A of $13.36M, raised on Jun 2008.
Curetis has 55 employees.
The company was founded in 2007 in Holzgerlingen, Germany, and operates in the molecular diagnostics sector. A platform for detecting infectious diseases through multiparameter PCR testing is developed, targeting bacterial infections in hospitalized patients. The Unyvero A50 System is utilized with various cartridges to identify pathogens and resistance genes for conditions like pneumonia and implant infections, with results obtained in 4-5 hours.
Curetis offers Unyvero and Unyvero A50 Solution.
Curetis has 13 investors. Key investors include Qiagen, OpGen, European Investment Bank, KfW, and BMBF.
Curetis operates through Curetis Gmbh..
Yes. Curetis was acquired by OpGen in September 2019.